DUBLIN, April 8, 2022 /PRNewswire/ — The “Global Brain Tumor Drugs Market Report 2022, Type, Drugs, End User” report has been added to from ResearchAndMarkets.com offer.

This report provides strategists, marketers, and senior management with the critical information they need to assess the Global Brain Tumor Drugs Market in the wake of the COVID-19 shutdown.

Reasons to buy

  • Get a truly global perspective with the most comprehensive report available on this market covering over 12 geographies.
  • Understand how the market is affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus diminishes.
  • Create regional and national strategies based on local data and analysis.
  • Identify growth segments for investment.
  • Outperform your competition using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research.
  • Benchmark performance against leading competitors.
  • Use relationships between key data sets for better strategy.
  • Suitable to support your internal and external presentations with reliable high quality data and analysis

Major players in the Brain Tumor Drugs Market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation, and GE Healthcare.

The Global Brain Tumor Drugs Market is Expected to Grow from $3.17 billion in 2021 for $3.49 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of business activities that resulted in operational challenges. The market should reach $4.84 billion in 2026 at a CAGR of 8.5%.

The brain tumor drugs market consists of the sale of drugs used to treat massive growth of abnormal cells in the human brain. These drugs are used alone or in combination, depending on the type, size, and location of the tumor.

The main types of drugs found in brain tumors are temozolomide, carmustine, cisplatin, bevacizumab, geftinib, and erlotinib. Temozolomide is a medicine to treat certain types of brain cancer (eg, glioblastoma multiforme, anaplastic astrocytoma) in people whose tumors have come back or who have recently been diagnosed with tumors. It is in a class of drugs called antineoplastics (cancer drugs). The different types include medulloblastoma, astrocytoma, oligodendroglioma, primary neuroectoderma (PNET), others (glioma, acoustic neuroma, meningioma) and are used in various sectors such as hospital pharmacies, clinics and others.

North America is the largest region in the Brain Tumor Drugs Market in 2021. Middle East is expected to be the fastest growing region during the forecast period. The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The major driving factor responsible for the growth of the brain tumor market is the rising prevalence of neurological disorders across the world. Neurological disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increased exposure to infections, and sedentary lifestyle. For example, according to the National Brain Tumor Society, about 700,000 people in United States around 700,000 people have a primary brain tumor in 2019 and around 86,000 more will be diagnosed. The increasing number of patients with neurological disorders, especially brain tumors, leads to an increase in demand for the drugs used in their treatment.

The increasing use of targeted therapies is acting as a drag on the brain tumor drug market. Targeted cancer therapies are drugs or substances that block cancer growth by interfering with molecules that are more specifically involved in cancer cell progression than normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells from the body while leaving normal cells unharmed. By focusing on cancer-specific cellular changes, this therapy may prove more effective than traditional chemotherapy and radiation therapy. For example, everolimus is a targeted therapy that specifically prevents cancer cells from growing and spreading. Similarly, bevacizumab prevents the regeneration of cancer cells unlike chemical drugs which cannot prevent regeneration. This growing popularity of targeted therapies is expected to affect the sales of conventional chemical brain tumor drugs, thereby restraining the market growth over the forecast period.

Companies in the brain tumor market are focusing on the use of nanotechnology for treatment. Nanoparticles are used to transport drugs in combination, directly to cancer cells or into the tumor. This technology has also reduced drug dosage, improved shelf life and reduced toxicity. A few nanomedicines are proving useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of brain tumors.

The brain tumor market is governed by regulatory authorities such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). The regulator requires companies in the sector to adhere to the same rules for conducting clinical trials, consistently across the region. These rules concern the transparency of information and the maintenance of safety standards when carrying out clinical trials of newly discovered medicines and therapies across the EU. The regulation also encourages cross-border cooperation to expand the scope of these clinical trials.

Main topics covered:

1. Summary

2. Characteristics of Brain Tumor Drugs Market

3. Brain Tumor Drugs Market Trends and Strategies

4. Impact of COVID-19 on brain tumor drugs

5. Brain Tumor Drugs Market Size and Growth
5.1. Global Historical Brain Tumor Drug Market, 2016-2021, USD Billion
5.1.1. Market Drivers
5.1.2. Market Constraints
5.2. Global Brain Tumor Drugs Market Forecast, 2021-2026F, 2031F, Billion USD
5.2.1. Market Drivers
5.2.2. Market Constraints

6. Brain Tumor Drugs Market Segmentation
6.1. Global Brain Tumor Drugs Market, Segmentation by Type, History & Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD

  • Medulloblastoma
  • Astrocytoma
  • Oligodendroglioma
  • Primary Neuroectodermal (PNET)
  • Others (glioma, acoustic neuroma, meningioma)

6.2. Global Brain Tumor Drugs Market, Segmentation by Drugs, History and Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD

  • Temozolomide
  • Carmustine
  • Cisplatin
  • Bevacizumab
  • Geftinib
  • Erlotinib

6.3. Global Brain Tumor Drugs Market, Segmentation by End User, History and Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD

  • Hospital pharmacies
  • Clinics
  • Others

7. Regional and Country Analysis of Brain Tumor Drugs Market
7.1. Global Brain Tumor Drugs Market, Split by Region, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion
7.2. Global Brain Tumor Drugs Market, Split by Country, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

For more information on this report, visit https://www.researchandmarkets.com/r/77egu5

Media Contact:
Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets